Rockwood Holdings to buy Talison Lithium for C$724 Million

Specialty chemicals producer Rockwood Holdings agreed to buy Talison Lithium for C$724 million ($729 million) to boost its output of lithium used in batteries and smartphones.

Demand for lithium batteries has risen in recent years as they are more efficient and help cut carbon emissions. The rising popularity of smartphones has also helped drive up prices of the metal.

Rockwood, whose peers include Kronos Worldwide, Sensient Technologies, WR Grace and Co and Valhi, has said it expects battery-grade lithium products to show double-digit sales growth this year.

Lithium business accounted for 14% of Rockwood's June quarter sales of $905.6 million.

Talison Lithium exports over 350,000 tons of lithium products annually, according to the company's website.

The company's Greenbushes operations in Western Australia has been producing lithium for over 25 years.

Rockwood said on Thursday it will pay C$6.50 per Talison share - a 53% premium to the stock's Wednesday close on the Toronto Stock Exchange.

Rockwood said it plans to finance the acquisition using cash on hand and new debt financing.

Lazard advised Rockwood while Macquarie Capital in Australia and Canada are acting as financial advisers to Talison.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.